Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00376181 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 3
- Development phase
- 96
- Enrollment target
NCT00376181 is a Phase 3 study that was terminated before completion, run by Takeda. The registered enrollment target is 96 participants.
The verdict
NCT00376181, a Phase 3 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of pioglitazone-azilsartan, once daily (QD), in subjects with type 2 diabetes mellitus with poor glycemic control.
Interventions
- DRUG Pioglitazone
- DRUG Pioglitazone and Azilsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00376181
The ClinicalTrials.gov registry entry for NCT00376181 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT00376181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00376181 about?
NCT00376181 is a clinical study titled "Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy and safety of pioglitazone-azilsartan, once daily (QD), in subjects with type 2 diabetes mellitus with poor glycemic control.
What is the current status of trial NCT00376181?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 96 participants. The study started on 2006-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00376181?
The interventions under investigation include: Pioglitazone (DRUG), Pioglitazone and Azilsartan (DRUG).
Who is sponsoring clinical trial NCT00376181?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.